Primary objectives:1) to determine the residual disease activity in a large cohort of patients with PsA in whom the treating physician considers the disease adequate-controlled under the current treatment.2) to document the different treatment…
ID
Source
Brief title
Condition
- Autoimmune disorders
- Joint disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
- Disease activity will be assessed in all potential disease domains.
- The proportion of patients that fulfills the criteria for Minimal Disease
Activity (MDA) will be determined.
- The proportion of patients that fulfills the criteria for MDA in DMARD
treated versus TNFi treated patients.
- Current medication (type, dosage and start date) will be documented
Secondary outcome
- Parameters related to cardiovascular outcomes will be assessed.
- Depression, quality of life, and work participation.
- Determination of biomarkers and genetic markers
Background summary
Psoriatic arthritis (PsA) is a chronic inflammatory disease. Treatment with
traditional disease modifying anti-rheumatic drugs (DMARDs) or biological
agents, including TNF inhibitors may be necessary to reduce the signs and
symptoms of disease, and prevent joint damage. Ideally, the treating physician
evaluates the symptoms and severity in all disease domains where PsA may be
active; skin and nails, arthritis, dactylitis, enthesitis and spondylitis but
also inflammatory bowel disease and uveitis. The 'tight control' and
'treat-to-target' principles that are commonly applied in rheumatoid arthritis
(RA) have not yet been evaluated and or implemented in PsA. This "tight
control" for PsA as well can be induced by using the criteria for "minimal
active disease". Our hypothesis is that a significant proportion of PsA
patients still have residual disease activity and thus may theoretically
benefit from more intensive treatment (after future studies).
Study objective
Primary objectives:
1) to determine the residual disease activity in a large cohort of patients
with PsA in whom the treating physician considers the disease
adequate-controlled under the current treatment.
2) to document the different treatment regimens in these patients.
Secondary objectives
1) to determine prevalence of other important co-morbidities, including the
cardiovascular disease, depression and alcohol (ab)use
2) to determine which biomarkers are able to predict MDA
Study design
A *two center* cross-sectional descriptive cohort study in patients with PsA in
whom the treating physician considers the disease is well-controlled. Patients
will be recruited from the outpatient clinic in Reade and AMC regardless of
treatment regimen.
Study burden and risks
- 1 visit (1,5 hours) is planned.
- a questionnaire will be performed with a duration of 15 minutes
- 1x blood will be drawn. The total amount is 37ml (8 tubes)
Meibergdreef 9
Amsterdam 1105 AZ
NL
Meibergdreef 9
Amsterdam 1105 AZ
NL
Listed location countries
Age
Inclusion criteria
psoriatic arthritis en voldoen aan classificatie criteria for psoriatic arthritis (CASPAR)
low disease activity according to rheumatologist no matter what therapy
Exclusion criteria
concomittant rheumatic diseases other than psoriatic arthritis
other painful conditions that may interfere the disease activiity evaluations
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL42303.018.12 |